Mineralys Therapeutics reports positive Phase 2 Advance-HTN trial results for lorundrostat in hypertension

Mineralys Therapeutics, Inc.

Lorundrostat 50 mg achieved a 7.9 mmHg placebo-adjusted reduction in 24-hour SBP at week 12 (p=0.001).
41% of lorundrostat patients achieved 24-hour SBP <125 mmHg at week 4 vs 18% on placebo (p<0.001).
Trial enrolled 53% Black and 40% female patients; safety showed low discontinuation and confirmed hyperkalemia rates of 2.1% and 3.2%.
Company plans to provide additional Phase 3 Launch-HTN data at an upcoming medical conference.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.